Illustration of a doctor discussing positive kidney treatment results with a patient using digital graphs.
Bild genererad av AI

Finerenon bromsar försämring av njurfunktion i studie på icke-diabetiker med kronisk njursjukdom; sammanslagen analys tyder på bredare fördelar vid CKD

Bild genererad av AI
Faktagranskad
Svenska

Nya data som presenterades vid European Renal Associations 63:e kongress i Glasgow och publicerades i tre ledande medicinska tidskrifter visar att finerenon bromsade försämringen av njurfunktionen hos vuxna med kronisk njursjukdom (CKD) utan diabetes samt minskade risken för kombinerade njur- och hjärt-kärlhändelser. En separat sammanslagen analys som kombinerade resultat från flera finerenon-studier rapporterade också färre händelser relaterade till njursvikt och hjärtsvikt i en bredare CKD-population.

Forskare presenterade resultaten vid European Renal Association (ERA) 63:e kongress i Glasgow, Skottland, samtidigt som artiklar publicerades i The New England Journal of Medicine, JAMA och The Lancet.

Vad folk säger

De första reaktionerna på X lyfter fram positiva resultat från FIND-CKD-studien som visar att finerenon bromsar eGFR-försämring hos patienter med CKD utan diabetes, med en riskminskning på 23 procent för njur- och hjärt-kärlhändelser, samt liknande fördelar i sammanslagna analyser för bredare CKD-populationer. Medicinska experter och tidskrifter uttrycker entusiasm över möjligheten att utöka indikationsområdet till att omfatta även patientgrupper utan diabetes.

Relaterade artiklar

Clinical illustration of nurse giving single-dose zilebesiran injection to hypertension patient, with blood pressure monitor showing reduction from KARDIA-2 trial results.
Bild genererad av AI

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Rapporterad av AI Bild genererad av AI Faktagranskad

A single, under-the-skin dose of the investigational RNA-interference drug zilebesiran lowered blood pressure when added to standard therapy in adults whose hypertension remained uncontrolled, according to results from the global Phase 2 KARDIA-2 trial of 663 participants published in JAMA.

FDA approves Travere Therapeutics' FILSPARI for FSGS

The U.S. Food and Drug Administration approved FILSPARI, developed by Travere Therapeutics, as the first medicine for focal segmental glomerulosclerosis (FSGS). Travere announced the approval on April 13, 2026. Company executives held a business update conference call that evening to discuss the milestone.

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Rapporterad av AI Faktagranskad

Researchers in Barcelona report that the lipid drug pemafibrate and the blood-pressure medicine telmisartan reduced diet-induced liver fat in rats and in a zebrafish model of fatty liver disease, with a half-dose combination performing as well as full doses of either drug alone. The work, published in Pharmacological Research, also describes a role for the PCK1 protein in telmisartan’s liver effects and argues that clinical trials would be needed to confirm any benefit in people.

Hälsa

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

Hälsa

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

Hälsa

Longevity startup doses first patient in vision loss trial

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

A randomized, placebo-controlled trial led by Australia’s Garvan Institute of Medical Research found that metformin, a long-used and low-cost drug for type 2 diabetes, did not improve clamp-measured insulin resistance in adults with type 1 diabetes but was associated with roughly 12% lower insulin requirements while blood sugar measures remained broadly unchanged.

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Rapporterad av AI

Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.

28 maj 2026 16:21

Gene-editing drug slashes bad cholesterol 62 percent in trial

25 maj 2026 16:39

Study finds beta blockers offer no benefit after uncomplicated heart attacks

21 maj 2026 22:41

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

6 maj 2026 06:50

Innovative Cape Town clinic boosts outcomes for young kidney patients

1 maj 2026 10:29

Smart water bottles and coaching increased hydration but did not cut kidney stone recurrences, trial finds

15 april 2026 12:08

Hitting urate targets with gout-lowering therapy is linked to lower cardiovascular risk in large UK study

9 april 2026 23:54

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Denna webbplats använder cookies

Vi använder cookies för analys för att förbättra vår webbplats. Läs vår integritetspolicy för mer information.
Avböj